CLOs on the Move

Amicus Therapeutics

www.amicusrx.com

 
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.amicusrx.com
  • 1 Cedar Brook Drive
    Cranbury, NJ USA 08512
  • Phone: 609.662.2000

Executives

Name Title Contact Details
Sergey Tesler
Executive Director, Global Regulatory Strategy, CMC Profile
Patrik Florencio
SVP, Global Chief Compliance and Risk Officer Profile
Ellen Rosenberg
Chief Legal Officer Profile
Heather Ramirez
Executive Director - Lead Counsel US Profile

Similar Companies

NEW Health Programs Association

NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify.   We believe that all people deserve...

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.

Afexa Life Sciences

Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sorenson Forensics

Sorenson Forensics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EIP Pharma

EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.